SCHEMBL7085162

SCHEMBL7085162

CCCCc1ccc(-c2[nH]c(C(F)(F)F)nc2-c2ccc(S(N)(=O)=O)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA2 P00918 8/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
PDPK1 O15530 3/20 0.53
CA1 P00915 5/20 0.45
CA9 Q16790 5/20 0.45
CA12 O43570 3/20 0.45
GCGR P47871 1/20 0.44
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
ALOX5 P09917 1/20 0.43
PTGS1 P23219 2/20 0.43
KIT P10721 1/20 0.41
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
PTGS2 P35354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7089397 0.90 PTGS1 (0.51) SMN1; SMN2GCGRESR1ESR2ALOX5
SCHEMBL7090091 0.89 CA2 (0.50) CA2PDPK1ESR1ESR2ALOX5
SCHEMBL7084388 0.86 CA1 (0.55) CA2CA1CA9CA12ESR1
SCHEMBL7087388 0.83 PTGS2 (0.50) CA2PDPK1CA1CA9CA12
SCHEMBL7085186 0.81 ALOX5 (0.62) SMN1; SMN2ESR1ESR2ALOX5PTGS1
SCHEMBL7090916 0.81 ESR1 (0.65) CA2CA1CA9CA12ESR1
SCHEMBL7084839 0.81 KIF11 (0.59) CA2PDPK1CA1CA9CA12
SCHEMBL7088536 0.80 PTGS2 (0.51) CA2PDPK1CA1CA9CA12
SCHEMBL7089340 0.80 CA2 (0.50) CA2CA1CA9CA12GCGR
SCHEMBL7089441 0.80 PTGS1 (0.50) CA2CA1CA9CA12ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5620999-A ANTIARTHRITIC, ANALGESIC AND ANTIPYRATIC AGENT G.D. SEARLE & CO. 1997-04-15 US claimed
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
EP-0772601-B1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
EP-1211244-A2 4,5-substitued imidazolyl compounds for the treatment of inflammation G.D. Searle & Co. (US) 2002-06-05 EP disclosed
EP-0772601-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-05-14 EP disclosed
US-5620999-A ANTIARTHRITIC, ANALGESIC AND ANTIPYRATIC AGENT G.D. SEARLE & CO. 1997-04-15 US disclosed
WO-1996003387-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 CA2 3267/4885SMN1; SMN2 3814/4885PDPK1 1496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.